Physician profile

Adel R Malati

Internal Medicine · Okmulgee, OK

NPI 1740286467

$1,618.26

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Avanir Pharmaceuticals, INC. $232.24 2019-2021
Pfizer INC. $145.82 2019-2021
Sunovion Pharmaceuticals INC. $138.41 2019-2020
Glaxosmithkline, LLC. $127.96 2020-2021
Novo Nordisk INC $112.80 2019-2021
Otsuka America Pharmaceutical, INC. $98.24 2019-2021
Astellas Pharma US INC $98.03 2019-2021
Lilly USA, LLC $90.68 2020-2021
Janssen Pharmaceuticals, INC $82.83 2019-2021
Novartis Pharmaceuticals Corporation $74.35 2019-2021
Acadia Pharmaceuticals INC $73.44 2019-2021
Supernus Pharmaceuticals, INC. $63.57 2019-2021
Allergan, INC. $53.43 2020
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $48.68 2020-2021
Abbvie INC. $44.03 2021
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Ucb, INC. $40.05 2020-2021
Sun Pharmaceutical Industries INC. $22.19 2020
Amarin Pharma, INC. $17.47 2021
Boehringer Ingelheim Pharmaceuticals, INC. $15.80 2019
Biogen, INC. $13.97 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $12.42 2021
E.R. Squibb & Sons, L.L.C. $11.85 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Adel R Malati

$1,618.26

in general payments reported 2019-2025

Years
2019-2021
Top company
Avanir Pharmaceuticals, INC.

https://glasscript.com/doctor/982467/adel-r-malati

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.